Publications

February 1, 2021

CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma

January 1, 2021

CAR-NK cell immunotherapy: Development and challenges toward an off-the-shelf product

August 3, 2020

iPSC-derived natural killer cells expressing EGFR-CAR against glioblastoma

November 4, 2017

The Broad Spectrum of Human Natural Killer Cell Diversity

July 1, 2015

CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells

April 1, 2014

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

December 1, 2013

Location and cellular stages of natural killer cell development

September 1, 2010

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody